Phase 1b Open-label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial)
Latest Information Update: 22 May 2025
At a glance
- Drugs RAY 121 (Primary)
- Indications Antiphospholipid syndrome; Behcet's syndrome; Bullous pemphigoid; Dermatomyositis; Idiopathic thrombocytopenic purpura; Immune-mediated necrotising myopathy
- Focus Adverse reactions
- Acronyms RAINBOW
- Sponsors Chugai Pharmaceutical
Most Recent Events
- 08 Jul 2024 Status changed from not yet recruiting to recruiting.
- 22 Apr 2024 New trial record